Digital symptom monitoring for liver cancer patients in China
Official title: Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
Run by Peking University · NCT06938945 · Data updated 2026-11-12
This study is testing if a digital tool that helps liver cancer patients report their symptoms weekly can improve their health and communication with doctors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Peking University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Haidian, Beijing Municipality) |
| Status | Recruiting |
| Started | May 24, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT06938945 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 diagnosed with locally advanced or metastatic liver cancer who are undergoing or have completed PD-1 therapy.
✕Probably not a fit
Patients with cognitive impairments or those unable to understand their symptoms may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to develop a digital intervention model for patients with hepatocellular carcinoma (HCC) that focuses on patient-reported outcomes (PRO). Participants will be divided into an intervention group, which will report their symptoms weekly through a digital platform, and a control group. The study seeks to determine if regular symptom reporting can enhance self-management, improve communication with healthcare providers, and ultimately lead to better health outcomes. The effectiveness of this digital approach will be evaluated by comparing health outcomes between the two groups.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance symptom management and quality of life for liver cancer patients.
How similar studies have gone: Other studies have shown promise in using digital interventions for symptom management in cancer patients, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
The inclusion criteria for the participants are: (1) aged 18 to 75 years, (2) clinically diagnosed as HCC, (3) treated with immunotherapy, (4) able and willing to use smartphones or tablets to complete the follow-up process according to protocol and (5) can understand Mandarin Chinese. The exclusion criteria are: (1) cognitive deficits that would preclude recognizing of their own symptoms and feelings, (2) unable to understand the research content and/or questionnaires, (3) is going to take or having taken surgical resection or liver transplant, (4) currently participating in other clinical trials that may affect this study, or (5) having other malignant tumours.
Where it's running
-
China Center for Health Development Studies, Peking University
Haidian, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Yiqi Xia
- Email: 2211110248@stu.pku.edu.cn
- Phone: +86 137 2033 7686
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC
This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.